BioSpace News Archive

As the first treatment to gain FDA approval for metabolic dysfunction-associated steatohepatitis, Madrigal Pharmaceuticals’ Rezdiffra is poised to make a sizable impact on a condition with substantial unmet need.

The U.S. cell and gene therapy clinical trial services market size was valued at USD 9.10 billion in 2023 and is anticipated to reach around USD 71.54 billion by 2033, growing at a CAGR of 22.9% from 2024 to 2033.

According to the latest research by nova one advisor, the U.S. life science tools market size was valued at USD 57.19 billion in 2023 and is estimated to hit around USD 140.44 billion by 2033, growing at a noteworthy CAGR of 9.4% from 2024 to 2033.

Precision Biologics, Inc. reports its lead monoclonal antibody, NEO-201, targets circulating human naïve regulatory T cells (Tregs) in both healthy donors and cancer patients.

Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California.

HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the publication of “Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator” in the Journal of Medicinal Chemistry along with two poster presentations on this same molecule which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Element Biosciences, Inc., developer of pioneering technologies to empower science, has begun taking orders for AVITI24™ the first instrument to combine state-of-the-art sequencing and cyto-profiling into a single integrated biology platform, the company announced at the Annual Meeting of the American Association for Cancer Research.

Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled in the ARISE II U.S. FDA IDE research study, which aims to examine investigational MicroFat versus saline injection for the treatment of Knee Osteoarthritis (OA).

Life Molecular Imaging and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE’s radiopharmaceutical manufacturing site located in Cleveland, Ohio.

Analytics for Life, Inc. and CorVista Health Inc. announced the FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module.